Market Cap
$488.2M
KMDA
KAMADA LTD
$8.20 ▼ -3.07%
Prev close $8.46Market cap$488.2M
12-mo target$13.50 (+62.5%)
High Impact Filing (7/10) Biotech & Drug Discovery
Snapshot
The big-picture read on KMDA right now — valuation, ownership and activity at a glance.
Cap Size
Small Cap
Insider Activity
$0.00 buy / $1.7M sell
Insider Net $
-$1.7M
SEC Reports
14
Press Releases
4
Price chart 30d -0.8%
Daily candles (open–high–low–close) with volume. Green = up day, red = down day.
No data for this timeframe.
Vol
Recent activity
The latest filings, insider trades, analyst actions, press and options flow — newest first.
Sep 16, 2026 SEC Sep 3, 2026 SEC
Kamada Ltd's shelf registration statement on Form F-3 (File No. 333-298814) was declared effective by the SEC on Septemb
EFFECT — Impact 3/10
Sep 14, 2026 Insider
Tsur David sold 22,827 shares
Director @ $8.18 ($186.7K)
Sep 14, 2026 Insider
Livneh Nir acquired via exercise 10,000 shares
VP, General Counsel @ $5.37 ($53.7K)
Sep 14, 2026 Insider
Sep 10, 2026 SEC Livneh Nir surrendered for taxes 3,459 shares
VP, General Counsel @ $8.35 ($28.9K)
Kamada announced that CEO Amir London will present at the H.C. Wainwright 28th Annual Global Investment Conference on Se
6-K — Impact 2/10
Sep 10, 2026 other
Sep 3, 2026 Press Kamada to Present at the H.C. Wainwright 28th Annual Global Investment Conference
REHOVOT, Israel, and HOBOKEN, N.J., Sept. 10, 2026 (GLOBE NEWSWIRE) -- Kamada Ltd. (NASDAQ: KMDA; TA
Kamada announced a tax ruling from the Israel Tax Authority regarding its previously declared $0.17 per share cash divid
Impact 2/10
Kamada obtained a tax ruling from the Israel Tax Authority clarifying withholding tax procedures for its previously anno
6-K — Impact 2/10
Analyst ratings buy % +0.0%
How Wall Street rates the stock today, and the latest firm-by-firm actions.
Recent analyst actions
| Date | Firm | Action | Rating | Firm rating |
|---|---|---|---|---|
| Dec 9, 2025 | HC Wainwright & Co. | MAINTAIN | Buy | 43% |
| May 15, 2025 | Benchmark | REITERATE | Buy | 54% |
| Mar 21, 2025 | Benchmark | INITIATE | Buy | 54% |
| Mar 6, 2025 | HC Wainwright & Co. | REITERATE | Buy | 43% |
| Jan 10, 2025 | HC Wainwright & Co. | REITERATE | Buy | 43% |
| Nov 14, 2024 | HC Wainwright & Co. | REITERATE | Buy | 43% |
| Aug 15, 2024 | HC Wainwright & Co. | REITERATE | Buy | 43% |
| Jul 3, 2024 | Stifel | INITIATE | Buy | 54% |
| May 9, 2024 | HC Wainwright & Co. | REITERATE | Buy | 43% |
| Mar 7, 2024 | HC Wainwright & Co. | REITERATE | Buy | 43% |
Monthly consensus history
| Period | Str. Buy | Buy | Hold | Sell | Str. Sell | Buy % | Distribution |
|---|---|---|---|---|---|---|---|
| Sep 1, 2026 | 3 | 5 | 1 | 0 | 0 | 89% | |
| Aug 1, 2026 | 3 | 5 | 1 | 0 | 0 | 89% | |
| Jul 1, 2026 | 3 | 5 | 1 | 0 | 0 | 89% | |
| Jun 1, 2026 | 3 | 5 | 1 | 0 | 0 | 89% | |
| May 1, 2026 | 3 | 5 | 1 | 0 | 0 | 89% | |
| Apr 1, 2026 | 3 | 5 | 1 | 0 | 0 | 89% | |
| Mar 1, 2026 | 3 | 5 | 1 | 0 | 0 | 89% | |
| Feb 1, 2026 | 3 | 5 | 1 | 0 | 0 | 89% |
Price targets
Where 4 covering analysts think KMDA trades over the next 12 months.
$13.50 +62.5% upside Strong Buy
Current$8.31 Low$11.00 Median$14.00 High$15.00 4 analysts
$11.00$15.00
Analyst rating Strong Buy· 1.0/5 as of Oct 3, 2026
Reports & filings
AI-scored summaries of recent SEC filings and press releases, with sentiment and impact.
14 SEC filing reports analyzed · 5 bullish, 1 bearish, 0 mixed, 8 neutral · avg impact 4.1/10.Plus 4 press releases.
NEUTRALEFFECT3/10
Kamada Ltd's shelf registration statement on Form F-3 (File No. 333-298814) was declared effective b
Sep 16, 2026
NEUTRAL6-K2/10
Kamada announced that CEO Amir London will present at the H.C. Wainwright 28th Annual Global Investm
Sep 10, 2026
NEUTRAL6-K2/10
Kamada obtained a tax ruling from the Israel Tax Authority clarifying withholding tax procedures for
Sep 3, 2026
BULLISH6-K, PRESS-RELEASE6/10
Kamada Ltd. reported record-high revenue and profitability for the first six months of 2026 and decl
Aug 17, 2026
Upcoming & catalyst events
Scheduled dates plus disclosed catalysts — earnings, dividends, enforcement, FDA and clinical-trial events. Colored dot = impact.
Sep 10, 2026
other
Kamada to Present at the H.C. Wainwright 28th Annual Global Investment Conference
REHOVOT, Israel, and HOBOKEN, N.J., Sept. 10, 2026 (GLOBE NEWSWIRE) -- Kamada Ltd. (NASDAQ: KMDA; TASE: KMDA.TA), a global biopharmaceutical company w
Sep 8, 2026
Clinical Trial
Phase III, Efficacy and Safety of "Kamada-AAT for Inhalation"
Phase Phase 3 — TERMINATED
Sep 3, 2026
dividend
Kamada Updates on Withholding Tax Procedures on Previously Announced Cash Dividend to Shareholders
REHOVOT, Israel and HOBOKEN, N.J., Sept. 03, 2026 (GLOBE NEWSWIRE) -- Kamada Ltd. (the “Company”) (NASDAQ: KMDA; TASE: KMDA.TA), a global biopharmaceu
Aug 17, 2026
announcement
Kamada Declares Cash Dividend of $0.17 Per Share; The Company Reported Record-High Revenue and Profitability for First Six Months of 2026
Dividend to be Paid Consistent with the Company's Cash Dividend Policy Dividend to be Paid Consistent with the Company's Cash Dividend Policy
Aug 12, 2026
earnings
Kamada Reports Record-High First Half and Second Quarter 2026 Financial Results, Representing Double-Digit Profitable Growth and the Strongest in Kamada's History; Affirms 2026 Annual Guidance
REHOVOT, Israel and HOBOKEN, N.J., Aug. 12, 2026 (GLOBE NEWSWIRE) -- Kamada Ltd. (NASDAQ: KMDA; TASE: KMDA.TA), a global biopharmaceutical company wit
Earnings estimates
Forecast earnings per share and revenue by period — and whether estimates are rising.
| Period | EPS Est. | Range | Growth | 30d Rev | Up/Dn | Revenue | # |
|---|---|---|---|---|---|---|---|
| Next FY | $0.58 | $0.46–$0.71 | 20.8% | -3.4% | 1↑ 1↓ | $0.7B | 3 |
| Next Q | $0.12 | $0.09–$0.13 | 100.0% | -4.0% | 2↑ 0↓ | $0.2B | 4 |
| Current Q | $0.13 | $0.10–$0.16 | 41.7% | -3.8% | 1↑ 0↓ | $0.2B | 4 |
| Current FY | $0.48 | $0.42–$0.52 | 36.4% | -2.1% | 4↑ 0↓ | $0.6B | 4 |
Current-quarter EPS estimate — revision history
| When | EPS estimate | Change vs now |
|---|---|---|
| Current | $0.128 | — |
| 7d ago | $0.133 | -0.005 |
| 30d ago | $0.133 | -0.005 |
| 60d ago | $0.125 | +0.003 |
| 90d ago | $0.125 | +0.003 |
Insider activity
Buying and selling by company executives and directors (SEC Form 4).
19 insiders, 50 transactions. Net -$1.7M — $0.00 bought, $1.7M sold.
| Date | Insider | Title | Type | Shares | Price | Value |
|---|---|---|---|---|---|---|
| Sep 14, 2026 | Tsur David | Director | SELL | 22,827 | $8.18 | $186.7K |
| Sep 14, 2026 | Livneh Nir | VP, General Counsel | EXERCISE | 10,000 | $5.37 | $53.7K |
| Sep 14, 2026 | Livneh Nir | VP, General Counsel | TAX W/H | 3,459 | $8.35 | $28.9K |
| Sep 14, 2026 | Brenner Yael | VP Quality | EXERCISE | 5,000 | $5.93 | $29.6K |
| Sep 14, 2026 | Brenner Yael | VP Quality | TAX W/H | 1,371 | $8.36 | $11.5K |
| Sep 14, 2026 | Brenner Yael | VP Quality | EXERCISE | 6,500 | $5.93 | $38.5K |
| Sep 14, 2026 | Brenner Yael | VP Quality | TAX W/H | 1,783 | $8.36 | $14.9K |
| Sep 14, 2026 | Brenner Yael | VP Quality | EXERCISE | 5,464 | $5.93 | $32.4K |
| Sep 14, 2026 | Brenner Yael | VP Quality | TAX W/H | 1,499 | $8.35 | $12.5K |
| Sep 9, 2026 | Tsur David | Director | SELL | 175 | $8.26 | $1.4K |
Short interest & halts
FINRA semi-monthly short positions, Reg SHO threshold status, and recent trading halts for KMDA.
Shares short
160,819
Settlement Sep 15, 2026
Change vs prior
+2.6%
Semi-monthly cycle
Days to cover
1.0
At avg daily volume
Of shares outstanding
≈0.3%
Estimate — not % of float
All KMDA filing & press-release reports (18)
- EFFECT reportSep 16, 2026
- 6-K reportSep 10, 2026
- PRESS-RELEASE reportSep 3, 2026
- 6-K reportSep 3, 2026
- 6-K, PRESS-RELEASE reportAug 17, 2026
- 6-K reportAug 12, 2026
- 6-K reportAug 6, 2026
- 6-K reportAug 5, 2026
- 6-K reportJul 20, 2026
- 6-K reportJul 13, 2026
- 6-K reportJun 18, 2026
- 6-K reportJun 1, 2026
- PRESS-RELEASE reportMay 13, 2026
- 6-K reportMar 31, 2026
- 6-K reportMar 26, 2026
- PRESS-RELEASE reportMar 26, 2026
- PRESS-RELEASE reportMar 11, 2026
- PRESS-RELEASE reportMar 11, 2026